Estrogen - A Potential New Treatment for Women & Men with Schizophrenia

雌激素 - 女性潜在的新疗法

基本信息

  • 批准号:
    nhmrc : 143654
  • 负责人:
  • 金额:
    $ 15.17万
  • 依托单位:
  • 依托单位国家:
    澳大利亚
  • 项目类别:
    NHMRC Project Grants
  • 财政年份:
    2001
  • 资助国家:
    澳大利亚
  • 起止时间:
    2001-01-01 至 2003-12-31
  • 项目状态:
    已结题

项目摘要

Estrogen - the major female hormone, has been shown in animal studies to decrease the two main brain chemicals (dopamine and serotonin) that are implicated in causing schizophrenia. The effect of estrogen in the brain is similar to current antipsychotic drugs. We have carried out a study that showed that when we gave 12 young women with schizophrenia 100 micrograms of estrogen in a skin patch form plus standard antipsychotic drug treament they recovered more quickly than 12 young women who received standard antipsychotic drug treatment only. 100mcg is a safe dose of estrogen. In this proposal we want to expand and clarify the pilot study resutls by conducting a 28 day trial in a total of 60 women with schizophrenia. 30 women would receive 100 mcg skin patch estrogen plus antipsychotic medication and 30 women would receive antipsychotic medicationly only. We also tested the value of adding a very small dose of oral estrogen to antipsychotic drug treatment in five men with schizophrenia and found that they made a better recovery compared to five men who received standard antipsychotic drugs only. We trialled the use of estrogen for seven days in men, but this may not have been long enough to examine the real impact of estrogen treatment in men. In this proposal we want to conduct a 14 day trial in a total of 60 men with schizophrenia. 30 men would receive 2mg of oral estrogen plus antipsychotic drug treatment and their results would be compared with 30 men who received standard antipsychotic drug treatment plus a placebo tablet identical in appearance to estrogen. For 14 days, this low dose of estrogen is very safe. Potentially estrogen may be a useful addition to the current standard treatment of schizophrenia. It may decrease the duration of acute illness and in women it may have a role in preventing relapses of schizophrenia as well as improving the general health of women with schizophrenia.
动物研究表明,雌激素--女性的主要荷尔蒙--可以减少导致精神分裂症的两种主要大脑化学物质(多巴胺和5-羟色胺)。雌激素在大脑中的作用类似于目前的抗精神病药物。我们进行的一项研究表明,当我们给12名患有精神分裂症的年轻女性服用100微克雌激素贴片加标准抗精神病药物治疗时,她们比只接受标准抗精神病药物治疗的12名年轻女性恢复得更快。100mcg是安全剂量的雌激素。在这项提案中,我们希望通过对60名女性精神分裂症患者进行28天的试验来扩大和澄清先导性研究的结果。30名妇女将接受100微克的皮肤贴片雌激素加抗精神病药物治疗,30名妇女将仅接受抗精神病药物治疗。我们还测试了在5名男性精神分裂症患者的抗精神病药物治疗中添加非常小剂量的口服雌激素的价值,发现与只接受标准抗精神病药物治疗的5名男性相比,他们的康复情况更好。我们在男性身上试验了七天的雌激素使用,但这可能还不够长,不足以检查雌激素治疗对男性的真正影响。在这项提案中,我们希望在总共60名男性精神分裂症患者中进行14天的试验。30名男性将接受2毫克的口服雌激素和抗精神病药物治疗,他们的结果将与30名接受标准抗精神病药物治疗和外观与雌激素相同的安慰剂的男性进行比较。在14天内,这种低剂量的雌激素是非常安全的。潜在的雌激素可能是目前精神分裂症标准治疗的有用补充。它可以缩短急性疾病的持续时间,对妇女来说,它可能在预防精神分裂症复发以及改善患有精神分裂症的妇女的总体健康方面发挥作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Prof Jayashri Kulkarni其他文献

Prof Jayashri Kulkarni的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Prof Jayashri Kulkarni', 18)}}的其他基金

A randomised controlled trial of NMDA antagonist, memantine, for the treatment of borderline personality disorder
NMDA 拮抗剂美金刚治疗边缘性人格障碍的随机对照试验
  • 批准号:
    nhmrc : GNT1129815
  • 财政年份:
    2017
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Project Grants
A randomised controlled trial of NMDA antagonist, memantine, for the treatment of borderline personality disorder
NMDA 拮抗剂美金刚治疗边缘性人格障碍的随机对照试验
  • 批准号:
    nhmrc : 1129815
  • 财政年份:
    2017
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Project Grants
Adjunctive Hormone Therapy for Treatment Resistant Depression in Perimenopausal Women
辅助激素疗法治疗围绝经期女性难治性抑郁症
  • 批准号:
    nhmrc : 1049041
  • 财政年份:
    2013
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Project Grants
Transdermal testosterone therapy: a potential treatment for selective serotonin reuptake inhibitor (SSRI)-associated sexual dysfunction in women
透皮睾酮疗法:选择性血清素再摄取抑制剂(SSRI)相关女性性功能障碍的潜在治疗方法
  • 批准号:
    nhmrc : 1002921
  • 财政年份:
    2011
  • 资助金额:
    $ 15.17万
  • 项目类别:
    NHMRC Project Grants
Selective Estrogen Receptor Modulators (SERMs) A Potential Treatment for Psychotic Symptoms of Schizophrenia?
选择性雌激素受体调节剂(SERM)是精神分裂症精神病症状的潜在治疗方法吗?
  • 批准号:
    nhmrc : 546084
  • 财政年份:
    2009
  • 资助金额:
    $ 15.17万
  • 项目类别:
    NHMRC Project Grants
A double-blind sham controlled trial of rTMS in treatment resistant major depression
rTMS 治疗难治性重度抑郁症的双盲假对照试验
  • 批准号:
    nhmrc : 436710
  • 财政年份:
    2007
  • 资助金额:
    $ 15.17万
  • 项目类别:
    NHMRC Project Grants
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?
抗雌激素——女性双相情感障碍的潜在治疗方法?
  • 批准号:
    nhmrc : 284319
  • 财政年份:
    2004
  • 资助金额:
    $ 15.17万
  • 项目类别:
    NHMRC Project Grants

相似国自然基金

Transient Receptor Potential 通道 A1在膀胱过度活动症发病机制中的作用
  • 批准号:
    30801141
  • 批准年份:
    2008
  • 资助金额:
    28.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Development of new heavy-element-based oxide glass-ceramics and investigation of their potential as radiation detector materials
新型重元素氧化物玻璃陶瓷的开发及其作为辐射探测器材料的潜力研究
  • 批准号:
    23K19188
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Sourcing the next generation of lubricants: exploring the potential of new natural sources of lubricants for industrial applications
采购下一代润滑油:探索工业应用润滑油的新天然来源的潜力
  • 批准号:
    2883076
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Studentship
Breakthrough in the New Formenlehre: On the Musicological Potential of Music Theory and Analysis
新形式的突破:论音乐理论与分析的音乐学潜力
  • 批准号:
    2884601
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Studentship
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
  • 批准号:
    10603636
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
New potential to restore neuromuscular and joint function after ACL injury
ACL 损伤后恢复神经肌肉和关节功能的新潜力
  • 批准号:
    10980775
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
Dehydroamino acids in HIV-1 capsid and matrix proteins: new potential targets for viral inactivation
HIV-1衣壳和基质蛋白中的脱氢氨基酸:病毒灭活的新潜在靶点
  • 批准号:
    10762067
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
Developing new solutions and building capacity to unlock the potential of solar thermal in East Africa
开发新的解决方案并建设能力以释放东非太阳能热利用的潜力
  • 批准号:
    10046726
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Collaborative R&D
Long-term Measurements of OH Reactivity: A Potential New Metric for Air Quality
OH 反应性的长期测量:空气质量的潜在新指标
  • 批准号:
    2888065
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Studentship
Tiny RNAs as new potential biomarkers for gammaherpesvirus-driven neurological and central nervous system diseases
微小RNA作为伽马疱疹病毒驱动的神经和中枢神经系统疾病的新潜在生物标志物
  • 批准号:
    10727761
  • 财政年份:
    2023
  • 资助金额:
    $ 15.17万
  • 项目类别:
Validating a biomarker and new potential therapy target in blood cancers
验证血癌的生物标志物和新的潜在治疗靶点
  • 批准号:
    486438
  • 财政年份:
    2022
  • 资助金额:
    $ 15.17万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了